2019 Fiscal Year Final Research Report
PPARgamma nanomedicine that promotes cardiac healing after acute myocardial infarction
| Project/Area Number |
17K09590
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Keywords | 心筋梗塞 / 炎症 / マクロファージ / ナノテクノロジー |
|---|
| Outline of Final Research Achievements |
In a mouse model, myocardial ischemia-reperfusion causes sequential inflammation by M1 pro-inflammatory macrophages and M2 tissue healing macrophages. A nano-medicine containing PPAR gamma agonist pioglitazone, injected at repefusion, reduced infarct size by skewing macrophage polarity toward less-inflammatory, resulting in an inhibition of left ventricular remodeling and improvement of prognosis in the mouse model.
|
| Free Research Field |
循環器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
この研究により、急性心筋梗塞病態における急性炎症と組織修復の制御による新しい疾病治療コンセプトを示すとともに、ナノ医薬プラットフォームの有用性を示すことができた。
|
